Kala Pharmaceuticals
KALA- 1M
- -50.0%
Kala Pharmaceuticals in brief
Kala Pharmaceuticals is a listed company in the Biotechnology industry, based in Arlington, Massachusetts, USA. It was founded in 2009. Its market value was $3 M on 29 October 2026, which makes it the 27,306th largest listed company in the world and the 4,450th largest in the USA on this site. Avraham Minkowitz is its chief executive. Its shares trade under the symbol KALA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Kala Pharmaceuticals
Kala Pharmaceuticals is a Biopharmaceutical company committed to advancing the treatment of eye diseases. The company annual revenue is 6.36 million USD and 205 employees as on 2020. The headquarters is in USA.
Kala Pharmaceuticals timeline
- 2009
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- 🔔Initial public offering as Kala Pharmaceuticals, Inc.Final prospectus filed with the SEC on 20 July 2017; shares registered for exchange trading on 14 July 2017.
- 2021
- 💰Record revenue of $11 millionFY2021, the highest of the 4 years on record.
- 2023
- ✎Renamed KALA BIO, Inc.Formerly Kala Pharmaceuticals, Inc..
Events of Kala Pharmaceuticals from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,540 (Jan 2020) · #2,975 (Jan 2021) · #4,676 (Jan 2022) · #3,590 (Dec 2022) · #4,942 (Jul 2023) · #4,375 (Jan 2024) · #1,597 (Mar 2026) · #3,963 (Aug 2026) · #4,308 (Oct 2026) · #4,452 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.5×
- Free cash flow yield
- -2702.9%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -385.4%
- Liabilities / assets
- 26.2%
- Net debt
- $-22M
- Revenue growth
- -65.4%
- R&D / revenue
- 453.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-39M | $-27M | — |
| Dec 2024 | — | — | $-41M | $-39M | — |
| Dec 2023 | — | — | $-40M | $-42M | — |
| Dec 2022 | $4M | -65.4% | $-82M | $-45M | -1152.2% |
| Dec 2021 | $11M | +76.7% | $-130M | $-143M | -1268.7% |
| Dec 2020 | $6M | +4.8% | $-96M | $-104M | -1640.4% |
| Dec 2019 | $6M | — | $-88M | $-94M | -1554.4% |
| Dec 2018 | — | — | $-65M | $-67M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-32M | — | — | $-3.31 | — |
| Dec 2024 | $-29M | — | — | $-10.15 | — |
| Dec 2023 | $-28M | — | — | $-17.35 | — |
| Dec 2022 | $-79M | — | — | $-29.48 | — |
| Dec 2021 | $-108M | — | — | $-108.32 | — |
| Dec 2020 | $-91M | — | — | $-1.99 | — |
| Dec 2019 | $-93M | $1M | $-94M | $-2.76 | — |
| Dec 2018 | $-54M | $2M | $-56M | $-2.49 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportBylaws amended · Other events
- Nov 9, 20268-KCurrent reportResults of operations
- Nov 3, 20268-KCurrent reportShareholder vote
- Sep 24, 2026DEF 14AProxy statement
- Sep 10, 20268-KCurrent reportMaterial agreement
- Sep 9, 20268-KCurrent reportOther events
- Aug 28, 20268-KCurrent reportListing notice
- Aug 19, 202610-QQuarterly report · period to Jun 2026
- Jul 23, 20268-KCurrent reportOther events
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportBylaws amended · Other events
- Apr 15, 202610-KAnnual report · period to Dec 2025
Official filings of Kala Pharmaceuticals with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-39 M
- Net income
- $-27 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $9 M
- Total liabilities
- $2 M
- Total equity
- $7 M
As of December-2025
Top 16 institutional investors in Kala Pharmaceuticals#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 220,623 | 0 (0.00%) | 1.14% | $0 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 173,948 | +28,796 (+19.84%) | 0.90% | $0 M | Nov 6, 2026 |
| 3 | Vanguard Fiduciary Trust Co | 101,396 | 0 (0.00%) | 0.52% | $0 M | Nov 13, 2026 |
| 4 | State Street Corp | 88,570 | 0 (0.00%) | 0.46% | $0 M | Nov 12, 2026 |
| 5 | Renaissance Technologies LLC | 81,100 | New | 0.42% | $0 M | Nov 12, 2026 |
| 6 | Susquehanna International Group, LLP | 79,831 | New | 0.41% | $0 M | Nov 16, 2026 |
| 7 | BlackRock, Inc. | 71,446 | -96 (-0.13%) | 0.37% | $0 M | Nov 13, 2026 |
| 8 | Northern Trust Corp | 41,606 | 0 (0.00%) | 0.22% | $0 M | Nov 16, 2026 |
| 9 | UBS Group AG | 1,345 | -7,712 (-85.15%) | 0.01% | $0 M | Nov 10, 2026 |
| 10 | Morgan Stanley | 124 | +96 (+342.86%) | 0.00% | $0 M | Nov 13, 2026 |
| 11 | Tower Research Capital LLC (TRC) | 45 | -571 (-92.69%) | 0.00% | $0 M | Nov 16, 2026 |
| 12 | Bank Julius Baer & Co. Ltd, Zurich | 5 | New | 0.00% | $0 M | Oct 29, 2026 |
| 13 | Berthel, Fisher & Company Financial Services, Inc. | 3 | New | 0.00% | $0 M | Nov 13, 2026 |
| 14 | Barclays PLC | 1 | -607 (-99.84%) | 0.00% | $0 M | Nov 6, 2026 |
| 15 | Northwestern Mutual Wealth Management Co | 1 | New | 0.00% | $0 M | Nov 13, 2026 |
| 16 | Caitong International Asset Management Co., Ltd | 1 | -9 (-90.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Kala Pharmaceuticals#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 220,623 | $0 M | 1.1% | <0.01% | +264% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 5,633 | $0 M | 0.03% | <0.01% | −12% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 3,822 | $0 M | 0.02% | <0.01% | −90% | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 355 | $0 M | <0.01% | <0.01% | −52% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 236 | $0 M | <0.01% | <0.01% | −98% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 152 | $0 M | <0.01% | <0.01% | −98% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Kala Pharmaceuticals#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Mark T. IwickiDirector | Sell | -154,894 | $0.810 | $125 K | 103,540 | Form 4 |
| filed | Mary ReumuthCHIEF FINANCIAL OFFICER | Sell | -967 | $0.820 | $793 | 28,906 | Form 4 |
| filed | Todd BazemoreDirector | Sell | -47,768 | $0.830 | $40 K | 35,932 | Form 4 |
| filed | Mary ReumuthCHIEF FINANCIAL OFFICER | Sell | -32,230 | $0.830 | $27 K | 29,873 | Form 4 |
| filed | Darius KharabiCHIEF BUSINESS OFFICER | Sell | -20,806 | $0.830 | $17 K | 41,760 | Form 4 |
| filed | Romulus K. BrazzellSEE REMARKS | Sell | -46,748 | $0.830 | $39 K | 35,952 | Form 4 |
| filed | Julian BakerFormer 10% owner | Sellindirect | -50,640 | $1.380 | $70 K | 46,480 | Form 4 |
| filed | Julian BakerFormer 10% owner | Sellindirect | -462,967 | $1.380 | $639 K | 425,006 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Kala Pharmaceuticals#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-50 reverse split ; 1-for-50 reverse split ; 1-for-5.21 reverse split
Trading halts
- 2026-11-14 00:50 UTC, code T3, resumed 14:00 UTC
- 2026-08-28 13:38 UTC, code LUDP, resumed 13:43 UTC
- 2026-05-08 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-12-04 15:45 UTC, code LUDP, resumed 15:50 UTC
- 2025-09-29 14:57 UTC, code LUDP, resumed 15:02 UTC
Fails to deliver
- : 29,972 shares at $0.18
- : 20,045 shares at $0.18
- : 2,386 shares at $0.19
- : 516 shares at $0.36
- : 9,512 shares at $0.42
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Kala Pharmaceuticals scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-3.31 vs -10.15Diluted EPS -3.31 in fiscal 2025 against -10.15 the year before (report's currency).
- ✓Net income higher than five years earlier-$27 M-$27 M in fiscal 2025 against -$104 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$27 MNet income -$27 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-279.1%-279.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities3.8×Current ratio 3.81 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-11.9×Operating income -11.9 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year114.7%Diluted shares up 114.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Kala Pharmaceuticals: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0—— | 0—— | 0−100%— | 3.9−65.4%100% | 11+76.7%100% | 6.4+4.7%100% | 6.1—100% | — | 0—— | 0—— | |
| Research and development | 19−15.0%— | 22+18.9%— | 19+5.3%— | 18+53.3%454% | 12−37.3%102% | 18−32.7%288% | 27−6.9%449% | 29+1.0%— | 29+15.9%— | 25—— | |
| Selling, general and administrative | — | — | 21−68.4%— | 65−38.1%1671% | 105+29.6%935% | 81+24.7%1274% | 65+83.5%1070% | 35+226%— | 11—— | — | |
| General and administrative | 24+28.8%— | 18−10.8%— | 21—— | — | — | — | — | — | 11+42.2%— | 7.6—— | |
| Operating expenses | 39−4.4%— | 41+3.3%— | 40−53.7%— | 86−39.5%2199% | 141+37.9%1259% | 103+8.8%1613% | 94+45.7%1552% | 65+62.3%— | 40+22.1%— | 33—— | |
| Operating income | −39—— | −41—— | −40—— | −82—−2099% | −130—−1159% | −96—−1513% | −88—−1452% | −65—— | −40—— | −33—— | |
| Interest and finance income | 1.1−44.6%— | 2.1−24.2%— | 2.7+308%— | 0.7+538%17.1% | 0.1−78.9%0.9% | 0.5−79.1%7.7% | 2.4+39.7%38.8% | 1.7+220%— | 0.5+259%— | 0.1—— | |
| Interest expense and finance costs | 3.3−43.4%— | 5.8−0.5%— | 5.8−20.0%— | 7.3−13.3%187% | 8.4−2.4%74.6% | 8.6+1.3%135% | 8.5+156%140% | 3.3+225%— | 1.0+32.9%— | 0.8—— | |
| Other non-operating income (expense) | 12+393%— | 2.5—— | −2.5−107%— | 37—948% | −12—−110% | — | — | — | — | — | |
| Income tax | 0—— | 0—— | 0—— | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—— | 0—— | 0—— | |
| Net income including minority interests | −27—— | −39—— | −42—— | −45—−1152% | −143—−1269% | −104—−1640% | −94—−1553% | −67—— | −42—— | −33—— | |
| Net income attributable to shareholders | −27—— | −39—— | −42—— | −45—−1152% | −143—−1269% | −104—−1640% | −94—−1553% | −67—— | −42—— | −33—— | |
| Earnings per share, basic | -3.31—— | -10.15—— | -17.35—— | -29.48—— | -108.32r-2.19—— | -1.99—— | -2.76—— | -2.49—— | -3.71r-6.11—— | -28.07—— | |
| Earnings per share, diluted | -3.31—— | -10.15—— | -17.35—— | -29.48—— | -108.32r-2.19—— | -1.99—— | -2.76—— | -2.49—— | -3.71r-6.11—— | -28.07—— | |
| Shares, weighted average (basic) | 8.1+115%— | 3.8+56.1%— | 2.4+59.9%— | 1.5+15.5%— | 1.3r65−97.5%— | 52—— | — | — | — | — | |
| Shares, weighted average (diluted) | 8.1+115%— | 3.8+56.1%— | 2.4+59.9%— | 1.5+15.5%— | 1.3r65−97.5%— | 52+53.1%— | 34+27.9%— | 27+135%— | 11r6.9+863%— | 1.2—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.6−85.2%79.6% | 51+0.6%92.2% | 51−27.8%91.0% | 70−23.5%81.2% | 92+19.2%66.1% | 77−9.6%34.9% | 85−50.0%55.4% | 171+49.2%77.3% | 115+152%98.3% | 45—98.2% | |
| Short-term investments | — | — | — | — | — | 76—34.4% | — | — | — | — | |
| Receivables | — | — | — | 0.2−98.7%0.2% | 15+59.8%11.0% | 9.6−16.9%4.3% | 12—7.5% | — | — | — | |
| Inventory | — | — | — | — | 8.6+65.2%6.2% | 5.2+12.5%2.4% | 4.6+13.5%3.0% | 4.1—1.9% | — | — | |
| Other current assets | 1.9+19.6%20.4% | 1.6−18.2%2.9% | 2.0−74.8%3.5% | 7.9r7.7+26.6%9.0% | 6.2+106%4.4% | 3.0−21.4%1.4% | 3.8+702%2.5% | 0.5+143%0.2% | 0.2r0.2+378%0.2% | 0.0—0.1% | |
| Current assets | 9.5−82.0%100% | 53−0.1%95.2% | 53−38.5%94.5% | 86−30.9%99.0% | 124−27.4%89.2% | 171+62.5%77.3% | 105−40.4%68.4% | 177+53.7%80.1% | 115+153%98.9% | 46—98.5% | |
| Property, plant and equipment | — | 0.7−0.5%1.3% | 0.8+88.3%1.3% | 0.4−85.3%0.5% | 2.7−14.0%2.0% | 3.2+17.3%1.4% | 2.7+24.6%1.7% | 2.2+176%1.0% | 0.8+32.3%0.7% | 0.6—1.3% | |
| Right-of-use (leased) assets | — | 1.7−16.5%3.0% | 2.0+12556%3.6% | 0.0−98.8%0.0% | 1.3−95.3%0.9% | 28−6.5%12.6% | 30+0.7%19.3% | 30+7059%13.4% | 0.4—0.4% | — | |
| Total assets | 9.5−82.9%100% | 55−0.8%100% | 56−35.6%100% | 87−37.7%100% | 139−37.1%100% | 222+43.6%100% | 154−30.2%100% | 221+89.6%100% | 117r116+152%100% | 46—100% | |
| Accounts payable | 1.0+57.0%10.4% | 0.6−31.7%1.1% | 0.9−67.5%1.6% | 2.8−42.2%3.3% | 4.9+184%3.5% | 1.7−31.5%0.8% | 2.5−53.8%1.6% | 5.4+353%2.5% | 1.2+20.6%1.0% | 1.0—2.2% | |
| Debt due within a year | — | 10—18.6% | — | 5.0—5.8% | — | — | — | — | 6.7+1099%5.7% | 0.6—1.2% | |
| Current liabilities | 2.5−85.3%26.3% | 17+103%30.6% | 8.3−67.5%14.9% | 26−31.4%29.6% | 37+68.4%26.8% | 22−10.3%10.0% | 25+45.6%16.1% | 17+14.4%7.7% | 15r14+168%12.8% | 5.5—12.0% | |
| Long-term debt | — | 20−41.2%36.2% | 34−9.9%61.1% | 38−51.9%43.7% | 79+9.3%56.6% | 72+1.5%32.6% | 71+1.4%46.1% | 70+486%31.8% | 12+31.8%10.3% | 9.1—19.6% | |
| Lease liabilities (non-current) | — | 1.4−20.3%2.6% | 1.8—3.2% | — | 0.5—0.4% | — | — | — | — | — | |
| Non-current liabilities | — | 26−34.7%47.2% | 40−4.9%71.7% | 42−50.5%48.6% | 85−14.3%61.1% | 99−0.5%44.8% | 100+0.9%64.7% | 99+725%44.8% | 12r12+18.1%10.3% | 10—21.9% | |
| Total liabilities | 2.5−94.2%26.3% | 43−10.9%77.8% | 48−28.6%86.6% | 68−44.7%78.1% | 123+0.8%87.9% | 122−2.4%54.9% | 125+7.5%80.8% | 116+332%52.5% | 27r26+71.1%23.1% | 16—33.9% | |
| Retained earnings | −695—−7322% | −668—−1204% | −629—−1125% | −587—−676% | −542—−389% | −400—−180% | −295—−191% | −201—−91.0% | −134—−115% | −92—−199% | |
| Shareholders' equity | 7.0−43.3%73.7% | 12+64.3%22.2% | 7.5−60.5%13.4% | 19+12.9%21.9% | 17−83.2%12.1% | 100+237%45.1% | 30−71.7%19.2% | 105+17.1%47.5% | 90—76.9% | −88—−189% | |
| Total liabilities and equity | 9.5−82.9%100% | 55−0.8%100% | 56−35.6%100% | 87−37.7%100% | 139−37.1%100% | 222+43.6%100% | 154−30.2%100% | 221+89.6%100% | 117r116+152%100% | 46—100% | |
| Shares outstanding | 0.6r28−90.9%— | 6.1+121%— | 2.8+61.7%— | 1.7+29.1%— | 1.3r66−97.8%— | 59+63.3%— | 36+6.6%— | 34+38.0%— | 25+1977%— | 1.2—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.3+22.4%— | 0.3−14.5%— | 0.3−43.6%— | 0.5−44.9%13.8% | 1.0+6.9%8.7% | 0.9+8.2%14.3% | 0.8—13.9% | — | — | — | |
| Share-based compensation | 7.0−16.6%— | 8.4+12.4%— | 7.5+6.5%— | 7.0−56.4%180% | 16+20.9%143% | 13+33.2%209% | 10.0+16.0%164% | 8.6+141%— | 3.6+72.6%— | 2.1—— | |
| Cash from operating activities | −32—— | −29—— | −28—— | −79—−2027% | −108—−963% | −91—−1426% | −93—−1527% | −54—— | −34—— | −27—— | |
| Capital expenditure | — | — | — | — | — | — | −1.3—−22.0% | −1.6—— | −0.5—— | −0.2—— | |
| Acquisitions, net of cash acquired | — | — | — | — | −4.7—−41.4% | — | — | — | — | — | |
| Cash from investing activities | −0.0—— | −0.2—— | −0.4−101%— | 63−11.4%1611% | 71—630% | −78—−1229% | −1.3—−22.0% | −1.6—— | −0.5—— | −0.2—— | |
| Debt issued | — | — | — | — | 78—692% | — | — | 72+619%— | 10+650%— | 1.3—— | |
| Shares issued | 9.1+169%— | 3.4−81.7%— | 19+1689%— | 1.0−97.5%26.6% | 41−74.0%367% | 159+1782%2492% | 8.4−71.9%139% | 300.0%— | 30—— | — | |
| Cash from financing activities | −12−139%— | 30+251%— | 8.5—— | −7.9−119%−204% | 43−73.5%379% | 161+1688%2525% | 9.0−92.8%148% | 124+19.7%— | 104+54.3%— | 67—— | |
| Change in cash | −44−15353%— | 0.3—— | −20—— | −24−571%−620% | 5.1—45.6% | −8.3—−130% | −85−224%−1401% | 68−1.0%— | 69+74.0%— | 40—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | — | 0.1−99.1%— | 0.1−99.0%— | — | 6.1+18.6%— | 6.2+17.2%— | 6.1−4.7%— | — | 5.2−6.9%— | 5.3—— | 6.4—— | — | 5.6—— | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | — | — | 4.6*—— | 5.0—— | |
| General and administrative | 18−0.2%— | 1.7−64.2%— | 1.7−62.1%— | 9.9*+135%— | 4.5+3.0%— | 4.6+7.6%— | 4.6−15.3%— | 4.2*−9.1%— | 4.4−11.1%— | 4.3—— | 5.4—— | 4.6*—— | 5.0—— | |
| Operating expenses | 21−49.0%— | 1.7−84.4%— | 1.8−83.1%— | 10*+8.1%— | 7.2−27.5%— | 11+14.8%— | 11−10.6%— | 9.5*−1.7%— | 10.0+14.0%— | 9.6—— | 12—— | 9.6*—— | 8.8—— | |
| Operating income | −21—— | −1.7—— | −1.8—— | −10*—— | −7.2—— | −11—— | −11—— | −9.5*—— | −10.0—— | −9.6—— | −12—— | −9.6*—— | −8.8—— | |
| Interest and finance income | 0.5−74.8%— | 0.1−65.6%— | 0.1−84.0%— | 0*−100%— | 0.3−52.6%— | 0.4−19.2%— | 0.5−8.1%— | 0.5*−21.6%— | 0.6−19.5%— | 0.5—— | 0.5—— | 0.6*—— | 0.7—— | |
| Interest expense and finance costs | — | — | — | 0.1*−89.9%— | 1.0−34.8%— | 1.1−25.9%— | 1.1−25.0%— | 1.4*−5.2%— | 1.5+1.3%— | 1.5—— | 1.5—— | 1.5*—— | 1.5—— | |
| Other non-operating income (expense) | 11+178%— | 0.1—— | 0.2−89.5%— | 11*+750%— | −0.3−131%— | −0.1−588%— | 1.7+1289%— | 1.3*+29.4%— | 1.0+1690%— | 0.0—— | 0.1—— | 1.0*—— | 0.1—— | |
| Net income including minority interests | −10—— | −1.6*—— | −1.6—— | 0.7*—— | −7.6*—— | −11*—— | −8.9—— | −8.2*—— | −9.0*—— | −9.6*—— | −12—— | −8.6*—— | −8.7*—— | |
| Net income attributable to shareholders | −10—— | −1.6—— | −1.6—— | 0.7*—— | −7.6—— | −11—— | −8.9—— | −8.2*—— | −9.0—— | −9.6—— | −12—— | −8.6*—— | −8.7—— | |
| Earnings per share, basic | — | -21.32—— | -0.14—— | — | -1.07—— | -85.64r-1.71—— | -70.49r-1.41—— | — | -1.93—— | -3.16—— | -4.20—— | — | -3.41—— | |
| Earnings per share, diluted | — | -21.32—— | -0.14—— | — | -1.07—— | -85.64r-1.71—— | -70.49r-1.41—— | — | -1.93—— | -3.16—— | -4.20—— | — | -3.41—— | |
| Shares, weighted average (basic) | 0.1−43.1%— | 0.1−43.1%— | 12+9255%— | — | 7.0+52.2%— | 0.1r6.5−95.7%— | 0.1r6.3−95.5%— | — | 4.6+81.5%— | 3.0—— | 2.8—— | — | 2.6—— | |
| Shares, weighted average (diluted) | 0.1−43.1%— | 0.1−43.1%— | 12+9255%— | — | 7.0+52.2%— | 0.1r6.5−95.7%— | 0.1r6.3−95.5%— | — | 4.6+81.5%— | 3.0—— | 2.8—— | — | 2.6—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.2—2.2% | 0.2−99.3%2.2% | 1.8−95.8%14.3% | 7.6−85.2%79.6% | 21−57.1%84.3% | 32−41.1%88.6% | 42−12.9%87.5% | 51+0.6%92.2% | 49−12.2%91.0% | 54—88.0% | 48—91.4% | 51—91.0% | 56—91.7% | |
| Short-term investments | 7.0—66.2% | 7.0—66.2% | 7.0—56.8% | — | — | — | — | — | — | — | — | — | — | |
| Other current assets | 3.4—31.7% | 3.4+94.8%31.7% | 3.6+1.7%28.9% | 1.9+19.6%20.4% | 3.2+53.0%12.7% | 1.7−63.0%4.8% | 3.5+117%7.2% | 1.6−18.2%2.9% | 2.1+12.9%3.8% | 4.7—7.6% | 1.6—3.0% | 2.0—3.5% | 1.8—3.0% | |
| Current assets | 11—100% | 11−68.6%100% | 12−73.1%100% | 9.5−82.0%100% | 24−52.7%97.0% | 34−42.8%93.4% | 46−8.7%94.7% | 53−0.1%95.2% | 51−11.4%94.8% | 59—95.5% | 50—94.4% | 53—94.5% | 58—94.7% | |
| Property, plant and equipment | — | — | — | — | 0.6−20.9%2.4% | 0.7+6.5%1.8% | 0.7−2.7%1.4% | 0.7−0.5%1.3% | 0.8−5.0%1.4% | 0.6—1.0% | 0.7—1.3% | 0.8—1.3% | 0.8—1.3% | |
| Right-of-use (leased) assets | — | — | — | — | — | 1.5−19.1%4.2% | 1.6−17.7%3.3% | 1.7−16.5%3.0% | 1.8−15.4%3.3% | 1.9—3.0% | 1.9—3.7% | 2.0—3.6% | 2.1—3.4% | |
| Total assets | 11—100% | 11−70.6%100% | 12−74.5%100% | 9.5−82.9%100% | 25−53.7%100% | 36−41.5%100% | 48−9.0%100% | 55−0.8%100% | 54−11.5%100% | 62—100% | 53—100% | 56—100% | 61—100% | |
| Accounts payable | 1.1—10.8% | 1.1+73.6%10.8% | 1.0+12.1%8.5% | 1.0+57.0%10.4% | 0.9+29.0%3.7% | 0.7−1.1%1.8% | 0.9+27.2%1.9% | 0.6−31.7%1.1% | 0.7−9.7%1.3% | 0.7—1.1% | 0.7—1.4% | 0.9—1.6% | 0.8—1.3% | |
| Debt due within a year | — | — | — | — | 28+58.0%114% | 9.5−20.6%26.4% | 16+159%32.1% | 10—18.6% | 18—33.2% | 12—19.5% | 6.0—11.3% | — | — | |
| Current liabilities | 1.5—14.5% | 1.5−90.4%14.5% | 1.6−93.2%12.6% | 2.5−85.3%26.3% | 33+36.5%130% | 16−16.5%44.4% | 23+93.4%47.6% | 17+103%30.6% | 24+132%44.1% | 19—31.1% | 12—22.4% | 8.3—14.9% | 10—16.9% | |
| Long-term debt | — | — | — | — | — | 19−17.7%52.1% | 15−47.0%31.3% | 20−41.2%36.2% | 17−49.3%31.7% | 23—37.1% | 29—53.8% | 34—61.1% | 34—55.4% | |
| Lease liabilities (non-current) | — | — | — | — | 1.1−27.4%4.4% | 1.2−24.6%3.4% | 1.3−22.3%2.8% | 1.4−20.3%2.6% | 1.5−18.5%2.8% | 1.6—2.6% | 1.7—3.2% | 1.8—3.2% | 1.9—3.1% | |
| Non-current liabilities | — | — | — | — | 1.1−95.2%4.4% | 23−19.0%64.5% | 20−43.3%40.6% | 26−34.7%47.2% | 23−41.0%43.2% | 29—46.6% | 34—65.0% | 40—71.7% | 40—64.8% | |
| Total liabilities | 1.5—14.5% | 1.5−96.1%14.5% | 1.6−96.3%12.6% | 2.5−94.2%26.3% | 34−28.7%135% | 39−18.0%109% | 43−8.3%88.2% | 43−10.9%77.8% | 47−5.4%87.3% | 48—77.7% | 46—87.4% | 48—86.6% | 50—81.6% | |
| Retained earnings | −698—−6597% | −698—−6597% | −697—−5654% | −695—−7322% | −696—−2780% | −688—−1908% | −677—−1403% | −668—−1204% | −660—−1220% | −651—−1056% | −641—−1209% | −629—−1125% | −621—−1016% | |
| Shareholders' equity | 9.0—85.5% | 9.0—85.5% | 11+88.5%87.4% | 7.0−43.3%73.7% | −8.7−226%−34.6% | −3.2−123%−8.9% | 5.7−14.3%11.8% | 12+64.3%22.2% | 6.9−38.9%12.7% | 14—22.3% | 6.7—12.6% | 7.5—13.4% | 11—18.4% | |
| Total liabilities and equity | 11—100% | 11−70.6%100% | 12−74.5%100% | 9.5−82.9%100% | 25−53.7%100% | 36−41.5%100% | 48−9.0%100% | 55−0.8%100% | 54−11.5%100% | 62—100% | 53—100% | 56—100% | 61—100% | |
| Shares outstanding | 19—— | 19+190%— | 19+188%— | 0.6r28−90.9%— | 7.4+61.2%— | 6.7+45.2%— | 6.5+129%— | 6.1+121%— | 4.6+71.2%— | 4.6—— | 2.8—— | 2.8—— | 2.7—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | 0.1*−21.7%— | 0.1*+103%— | 0.1*+9.8%— | 0.1+3.0%— | 0.1*−1.4%— | 0.1*−20.3%— | 0.1*—— | 0.1—— | 0.1*—— | 0.1*—— | |
| Share-based compensation | 1.8−78.8%— | −0.1−106%— | −0.5−120%— | 0.4*−80.9%— | 2.0+0.4%— | 2.2+19.0%— | 2.3−2.8%— | 2.1*−11.8%— | 2.0−15.3%— | 1.9—— | 2.4—— | 2.4*—— | 2.4—— | |
| Cash from operating activities | −20—— | −1.5*—— | −2.9—— | −4.6*—— | −11*—— | −17—— | −8.8—— | −4.6*—— | −4.7*—— | −9.2*—— | −11—— | −7.7*—— | −3.0*—— | |
| Cash from investing activities | −7.0—— | 0*—— | −7.0—— | 0*—— | 0.0*—— | — | — | −0.1*—— | −0.1*−101%— | −0.0*—— | −0.0—— | −0.0*—— | 9.7*—— | |
| Shares issued | — | — | — | — | — | — | — | 0.9*+61.9%— | 4.9r0*—— | — | — | 0.6*—— | 0*—— | |
| Cash from financing activities | −4.9−228%— | 0*—— | 4.1—— | −9.0*−235%— | 0.0*—— | −2.5*−117%— | −0.1−102%— | 6.6*+162%— | −0.2*−550%— | 15*—— | 8.4—— | 2.5*—— | 0.0*—— | |
| Change in cash | −32—— | −1.5*—— | −5.8—— | −14*−784%— | −11*—— | −10*−280%— | −9.0—— | 2.0*—— | −5.0*−173%— | 5.7*—— | −2.4—— | −5.2*—— | 6.8*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Kala Pharmaceuticals#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Avraham Minkowitz | $907 K | −$1.0 M | $2.4 M | $1 |
| 2024Avraham Minkowitz | $1.5 M | $1.3 M | $935 K | $7 |
| 2023Avraham Minkowitz | $8.3 M | $3.7 M | $2.9 M | $2 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Kala Pharmaceuticals#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Auditor changed 2 · Debt called early 1 · Restructuring 3 · Change in control 1 · Directors and officers 8 · Material agreement 8 · Agreement ended 1 · New debt 2 · Unregistered share sale 5 · Shareholder rights changed 2 · Bylaws or fiscal year changed 4 · Shareholder vote 2 · Results announced 3
| Filed | What happened | Filing |
|---|---|---|
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Change in controlDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changedShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Auditor changedDirectors and officers | 8-K | |
| Auditor changed | 8-K | |
| Material agreement | 8-K | |
| Directors and officersMaterial agreementAgreement endedNew debtUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| RestructuringDirectors and officers | 8-K/A | |
| Debt called early | 8-K | |
| Restructuring | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
7 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2026 | $2 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| Jan 2026 | $2 M | Private placement after listing | $2 to $10 million | 20 | equity | SEC |
| Dec 2024 | $11 M | Private placement after listing | $10 to $50 million | 6 | equity | SEC |
| Jun 2024 | $13 M | Private placement after listing | $10 to $50 million | 5 | equity | SEC |
| Nov 2021 | $16 M | Private placement after listing | $10 to $50 million | 26 | equity | SEC |
| Apr 2016 | $68 M | No. 7 | $50 to $250 million | 25 | equity | SEC |
| Aug 2015 | $7 M | No. 6 | $2 to $10 million | 1 | equity | SEC |
| Apr 2014 | $23 M | No. 5 | $10 to $50 million | 16 | equity | SEC |
| Feb 2013 | $6 M | No. 4 | $2 to $10 million | 10 | equity | SEC |
| Feb 2012 | $7 M | No. 3 | $2 to $10 million | 10 | equity | SEC |
| Oct 2010 | $3 M | No. 2 | $2 to $10 million | 9 | equity, debt | SEC |
| Dec 2009 | $2 M | No. 1 | $2 to $10 million | 10 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Kala Pharmaceuticals#
1 labor condition applications certified in fiscal 2021 for 1 positions, at a median wage of $220 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Director, External ManufacturingIndustrial Engineers | 1 | $220 K |
Where: Bedford, MA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Kala Pharmaceuticals, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | 19 | · | · | · | 19 |
| 2022 | · | · | · | · | · | · | 113 | · | · | · | · | · | 113 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 19 people | Restructuring planSEC 8-K | “In connection with such decisions, the Board approved a reduction in the Company’s workforce by approximately 19 employees, or approximately 51% (the “Reduction”).” | Filing | |
| 19 people | Restructuring planSEC 8-K | “In connection with such decisions, the Board approved a reduction in the Company’s workforce by approximately 19 employees, or approximately 51% (the “Reduction”).” | Filing | |
| 113 people | Restructuring planSEC 8-K | “On June 16, 2022, the Board of Directors (the “Board”) of the Company committed to a course of action to terminate 113 employees, consisting of the Company’s entire commercial sale…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Kala Pharmaceuticals compares in Biotechnology
- Market cap$3 M · higher than 3% of 726
- Revenue growth-65.4% · higher than 13% of 438
- Price / book0.5× · lower than 92% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Kala Pharmaceuticals🇺🇸 | $3 M | — | — | -65.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Kala Pharmaceuticals? Verify and update this profile — free
Show Kala Pharmaceuticals's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.